Der­ma­van­t's Vta­ma works again in eczema as Roivant sub­sidiary seeks la­bel ex­pan­sion next year

Al­most a year to the day af­ter Der­ma­vant Sci­ences land­ed its first FDA ap­proval for plaque pso­ri­a­sis for Vta­ma, the drug­mak­er is out with its sec­ond suc­cess­ful Phase III tri­al of the top­i­cal cream for treat­ing eczema.

The Roivant sub­sidiary said the steroid-free, van­ish­ing cream worked again in a late-stage study iden­ti­cal to the first, which read out in March. With da­ta from a lit­tle more than 800 pa­tients across the two stud­ies, dubbed ADOR­ING 1 and 2, the com­pa­ny plans to ask the FDA for a la­bel ex­pan­sion in atopic der­mati­tis for adults and kids as young as age 2 in the first quar­ter of 2024.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER